# Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors

> **NCT07714395** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Actuate Therapeutics Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumor

## Interventions

- **DRUG:** Elraglusib Oral Tablets

## Key facts

- **NCT ID:** NCT07714395
- **Lead sponsor:** Actuate Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2029-07
- **Final completion:** 2029-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07714395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07714395, "Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07714395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*